Literature DB >> 16244583

Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma.

D Cvejic1, S Savin, I Petrovic, S Selemetjev, I Paunovic, S Tatic, M Havelka.   

Abstract

BACKGROUND AND AIM: To examine the relationship between galectin-3 and cell proliferation in thyroid tumor tissue. Galectin-3, a beta-galactoside binding protein, has recently been recognized as a promising molecular marker of thyroid malignancy, due to its high expression in thyroid carcinomas and absence from normal or benign thyroid tissue. However, its exact role in thyroid tumor biology is still unknown. PATIENTS AND METHODS: We examined the relationship between galectin-3 and cell proliferation by comparative immunostaining for galectin-3 and proliferating cell nuclear antigen (PCNA) in paraffin-embedded tissues from 126 cases of papillary thyroid carcinoma.
RESULTS: Positive cytoplasmic immunostaining for galectin-3 was found in 115 (91.3%) cases. Nuclear staining for PCNA was detectable in 93 (74.4%) cases. A low level of PCNA staining (less than 10% positive cells) was found in 36 (28.6%) cases, moderate staining for PCNA (more than 10% but less than 30% positive cells) in 35 cases (27.8%), while highly increased PCNA expression (more than 30% positive cells) was found in 32 (25.4%) cases. Moderate or strong galectin-3 expression, found in 99 cases, was associated with highly increased PCNA staining in 28.3% of them but with no detectable PCNA expression in 24.3% of them.
CONCLUSION: These results suggest that overexpression of galectin-3 is not clearly related to proliferative activity of papillary thyroid carcinoma cells as assessed by PCNA immunostaining.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16244583

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  8 in total

Review 1.  Diagnostic utility of galectin-3 in thyroid cancer.

Authors:  Connie G Chiu; Scott S Strugnell; Obi L Griffith; Steven J M Jones; Allen M Gown; Blair Walker; Ivan R Nabi; Sam M Wiseman
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

2.  Expression of galectin-3 in pancreatic ductal adenocarcinoma.

Authors:  Matthias M Gaida; Sylvia T Bach; Frank Günther; Billur Baseras; Darjus F Tschaharganeh; Thilo Welsch; Klaus Felix; Frank Bergmann; Gertrud M Hänsch; Moritz N Wente
Journal:  Pathol Oncol Res       Date:  2011-09-12       Impact factor: 3.201

3.  Survivin DEx3 as a biomarker of thyroid cancers: A study at the mRNA and protein level.

Authors:  Joanna Waligórska-Stachura; Nadia Sawicka-Gutaj; Maciej Zabel; Mirosław Andrusiewicz; Paweł Gut; Agata Czarnywojtek; Marek Ruchała
Journal:  Oncol Lett       Date:  2017-02-10       Impact factor: 2.967

4.  Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms.

Authors:  B S Sumana; Sampangiram Shashidhar; A S Shivarudrappa
Journal:  J Clin Diagn Res       Date:  2015-11-01

5.  The inactive form of glycogen synthase kinase-3β is associated with the development of carcinomas in galectin-3 wild-type mice, but not in galectin-3-deficient mice.

Authors:  Daniella Fernandes Mendonça; Roger Chammas; Fu-Tong Liu; Suely Nonogaki; Sergio Vitorino Cardoso; Adriano Mota Loyola; Paulo Rogério de Faria
Journal:  Int J Clin Exp Pathol       Date:  2012-07-17

6.  REGγ Is Associated with Lymph Node Metastasis and T-Stage in Papillary Thyroid Carcinoma.

Authors:  Long Qi; Wei He
Journal:  Med Sci Monit       Date:  2018-03-06

7.  Incidence of thyroid carcinomas in an extended retrospective study of 526 autopsies.

Authors:  Iuliana Sobaru Mohorea; Bogdan Socea; Dragoş Şerban; Zenaida Ceausu; Adrian Tulin; Violeta Melinte; Mihai Ceausu
Journal:  Exp Ther Med       Date:  2021-04-14       Impact factor: 2.447

8.  Galectin-1 gene silencing inhibits the activation and proliferation but induces the apoptosis of hepatic stellate cells from mice with liver fibrosis.

Authors:  Zhi-Jun Jiang; Qing-Hua Shen; Hai-Yong Chen; Zhe Yang; Ming-Qi Shuai; Shu-Sen Zheng
Journal:  Int J Mol Med       Date:  2018-10-23       Impact factor: 4.101

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.